Search research articles
Contact Us
Filters
Showing results (101-110 of 126) with videos related to
Page
of 13
Sort By:
British Journal of Cancer
|
January 23, 2014
Body mass index and circulating oestrone sulphate in women treated with adjuvant letrozole
V Sini, G Lunardi, M Cirillo, et al.
Cancer Treatment Reviews
|
January 13, 2023
Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review
F Miglietta, A Fabi, D Generali, et al.
Cancer Treatment Reviews
|
July 3, 2023
Corrigendum to "Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review" [Cancer Treat. Rev. 114 (2023) 102511]
F Miglietta, A Fabi, D Generali, et al.
Cancer Treatment Reviews
|
May 7, 2023
Corrigendum to "Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review" [Cancer Treatm. Rev. 114 (2023) 102511]
F Miglietta, A Fabi, D Generali, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 4, 2026
Trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of disease
G Curigliano, X Hu, R Dent, et al.
Obesity Surgery
|
October 4, 2005
BioEnterics Intragastric Balloon: The Italian Experience with 2,515 Patients
A Genco, T Bruni, S B Doldi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 5, 2021
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication
D Miles, E Ciruelos, A Schneeweiss, et al.
ESMO Open
|
January 22, 2025
Factors associated with first-to-second-line attrition among patients with metastatic breast cancer in the real world
E Blondeaux, L Boni, G Chilà, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 10, 2016
Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer
E Vrdoljak, N Marschner, C Zielinski, et al.
Surgery
|
November 18, 2005
Obese teenagers treated by Lap-Band System: the Italian experience
L Angrisani, F Favretti, F Furbetta, et al.
Page
of 13
Search research articles
Search
Showing results (101-110 of 126) with videos related to
Sort By:
Page
of 13
British Journal of Cancer
|
January 23, 2014
Body mass index and circulating oestrone sulphate in women treated with adjuvant letrozole
V Sini, G Lunardi, M Cirillo, et al.
Cancer Treatment Reviews
|
January 13, 2023
Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review
F Miglietta, A Fabi, D Generali, et al.
Cancer Treatment Reviews
|
July 3, 2023
Corrigendum to "Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review" [Cancer Treat. Rev. 114 (2023) 102511]
F Miglietta, A Fabi, D Generali, et al.
Cancer Treatment Reviews
|
May 7, 2023
Corrigendum to "Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review" [Cancer Treatm. Rev. 114 (2023) 102511]
F Miglietta, A Fabi, D Generali, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 4, 2026
Trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of disease
G Curigliano, X Hu, R Dent, et al.
Obesity Surgery
|
October 4, 2005
BioEnterics Intragastric Balloon: The Italian Experience with 2,515 Patients
A Genco, T Bruni, S B Doldi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 5, 2021
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication
D Miles, E Ciruelos, A Schneeweiss, et al.
ESMO Open
|
January 22, 2025
Factors associated with first-to-second-line attrition among patients with metastatic breast cancer in the real world
E Blondeaux, L Boni, G Chilà, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 10, 2016
Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer
E Vrdoljak, N Marschner, C Zielinski, et al.
Surgery
|
November 18, 2005
Obese teenagers treated by Lap-Band System: the Italian experience
L Angrisani, F Favretti, F Furbetta, et al.
Page
of 13